Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)

NCT07581314 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-Negative Breast Cancer (TNBC)
Advanced Triple-Negative Breast Cancer
Metastatic Triple-negative Breast Cancer

Interventions

DRUG: Zn-Telomir

Sponsor

Telomir Pharmaceuticals, Inc.